Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_assertion type Assertion NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_head.
- NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_assertion description "[The anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been used in patients with lung cancer or inflammatory myofibroblastic tumor (IMT), both types harboring ALK fusions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_provenance.
- NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_assertion evidence source_evidence_literature NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_provenance.
- NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_assertion SIO_000772 21430068 NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_provenance.
- NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_assertion wasDerivedFrom befree-2016 NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_provenance.
- NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_assertion wasGeneratedBy ECO_0000203 NP881769.RAVxoTOiJE-eC1f6lAA2GRc6ziCW1jldiNhPb-8uFw-jE130_provenance.